XML 37 R26.htm IDEA: XBRL DOCUMENT
v3.25.3

Revenue (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Revenue from Contract with Customer [Abstract] |
Schedule of Revenue by Sales Category | The following tables provide detail by sales category:
|  | Three Months Ended September 30, 2025 |  | Three Months Ended September 30, 2024
(in millions) |  | U.S. |  | Int’l |  | Total |  | U.S. |  | Int’l |  | Total
Established Pharmaceutical Products — |  |  |  |  |  |  |  |  |  |  |  |
Key Emerging Markets |  | $ | — |  |  | $ | 1,097 |  |  | $ | 1,097 |  |  | $ | — |  |  | $ | 994 |  |  | $ | 994 |
Other |  | — |  |  | 414 |  |  | 414 |  |  | — |  |  | 412 |  |  | 412 |
Total |  | — |  |  | 1,511 |  |  | 1,511 |  |  | — |  |  | 1,406 |  |  | 1,406 |
Nutritional Products — |  |  |  |  |  |  |  |  |  |  |  |
Pediatric Nutritionals |  | 520 |  |  | 457 |  |  | 977 |  |  | 568 |  |  | 387 |  |  | 955 |
Adult Nutritionals |  | 368 |  |  | 808 |  |  | 1,176 |  |  | 382 |  |  | 729 |  |  | 1,111 |
Total |  | 888 |  |  | 1,265 |  |  | 2,153 |  |  | 950 |  |  | 1,116 |  |  | 2,066 |
Diagnostic Products — |  |  |  |  |  |  |  |  |  |  |  |
Core Laboratory |  | 366 |  |  | 998 |  |  | 1,364 |  |  | 332 |  |  | 982 |  |  | 1,314 |
Molecular |  | 36 |  |  | 95 |  |  | 131 |  |  | 37 |  |  | 91 |  |  | 128 |
Point of Care |  | 111 |  |  | 47 |  |  | 158 |  |  | 103 |  |  | 43 |  |  | 146 |
Rapid Diagnostics |  | 373 |  |  | 227 |  |  | 600 |  |  | 560 |  |  | 264 |  |  | 824 |
Total |  | 886 |  |  | 1,367 |  |  | 2,253 |  |  | 1,032 |  |  | 1,380 |  |  | 2,412 |
Medical Devices — |  |  |  |  |  |  |  |  |  |  |  |
Rhythm Management |  | 350 |  |  | 336 |  |  | 686 |  |  | 288 |  |  | 309 |  |  | 597 |
Electrophysiology |  | 322 |  |  | 383 |  |  | 705 |  |  | 285 |  |  | 325 |  |  | 610 |
Heart Failure |  | 280 |  |  | 86 |  |  | 366 |  |  | 252 |  |  | 70 |  |  | 322 |
Vascular |  | 280 |  |  | 465 |  |  | 745 |  |  | 258 |  |  | 441 |  |  | 699 |
Structural Heart |  | 297 |  |  | 338 |  |  | 635 |  |  | 270 |  |  | 288 |  |  | 558 |
Neuromodulation |  | 196 |  |  | 58 |  |  | 254 |  |  | 190 |  |  | 46 |  |  | 236 |
Diabetes Care |  | 796 |  |  | 1,261 |  |  | 2,057 |  |  | 673 |  |  | 1,052 |  |  | 1,725 |
Total |  | 2,521 |  |  | 2,927 |  |  | 5,448 |  |  | 2,216 |  |  | 2,531 |  |  | 4,747 |
Other |  | 4 |  |  | — |  |  | 4 |  |  | 4 |  |  | — |  |  | 4 |
Total |  | $ | 4,299 |  |  | $ | 7,070 |  |  | $ | 11,369 |  |  | $ | 4,202 |  |  | $ | 6,433 |  |  | $ | 10,635 |
|  | Nine Months Ended September 30, 2025 |  | Nine Months Ended September 30, 2024
(in millions) |  | U.S. |  | Int’l |  | Total |  | U.S. |  | Int’l |  | Total
Established Pharmaceutical Products — |  |  |  |  |  |  |  |  |  |  |  |
Key Emerging Markets |  | $ | — |  |  | $ | 3,121 |  |  | $ | 3,121 |  |  | $ | — |  |  | $ | 2,910 |  |  | $ | 2,910 |
Other |  | — |  |  | 1,033 |  |  | 1,033 |  |  | — |  |  | 1,016 |  |  | 1,016 |
Total |  | — |  |  | 4,154 |  |  | 4,154 |  |  | — |  |  | 3,926 |  |  | 3,926 |
Nutritional Products — |  |  |  |  |  |  |  |  |  |  |  |
Pediatric Nutritionals |  | 1,695 |  |  | 1,377 |  |  | 3,072 |  |  | 1,646 |  |  | 1,377 |  |  | 3,023 |
Adult Nutritionals |  | 1,105 |  |  | 2,334 |  |  | 3,439 |  |  | 1,115 |  |  | 2,146 |  |  | 3,261 |
Total |  | 2,800 |  |  | 3,711 |  |  | 6,511 |  |  | 2,761 |  |  | 3,523 |  |  | 6,284 |
Diagnostic Products — |  |  |  |  |  |  |  |  |  |  |  |
Core Laboratory |  | 1,049 |  |  | 2,850 |  |  | 3,899 |  |  | 969 |  |  | 2,879 |  |  | 3,848 |
Molecular |  | 111 |  |  | 265 |  |  | 376 |  |  | 112 |  |  | 272 |  |  | 384 |
Point of Care |  | 315 |  |  | 133 |  |  | 448 |  |  | 308 |  |  | 133 |  |  | 441 |
Rapid Diagnostics |  | 1,093 |  |  | 664 |  |  | 1,757 |  |  | 1,386 |  |  | 762 |  |  | 2,148 |
Total |  | 2,568 |  |  | 3,912 |  |  | 6,480 |  |  | 2,775 |  |  | 4,046 |  |  | 6,821 |
Medical Devices — |  |  |  |  |  |  |  |  |  |  |  |
Rhythm Management |  | 994 |  |  | 950 |  |  | 1,944 |  |  | 851 |  |  | 915 |  |  | 1,766 |
Electrophysiology |  | 943 |  |  | 1,091 |  |  | 2,034 |  |  | 841 |  |  | 983 |  |  | 1,824 |
Heart Failure |  | 824 |  |  | 249 |  |  | 1,073 |  |  | 733 |  |  | 215 |  |  | 948 |
Vascular |  | 831 |  |  | 1,381 |  |  | 2,212 |  |  | 787 |  |  | 1,325 |  |  | 2,112 |
Structural Heart |  | 868 |  |  | 980 |  |  | 1,848 |  |  | 761 |  |  | 876 |  |  | 1,637 |
Neuromodulation |  | 565 |  |  | 171 |  |  | 736 |  |  | 563 |  |  | 142 |  |  | 705 |
Diabetes Care |  | 2,338 |  |  | 3,527 |  |  | 5,865 |  |  | 1,899 |  |  | 3,043 |  |  | 4,942 |
Total |  | 7,363 |  |  | 8,349 |  |  | 15,712 |  |  | 6,435 |  |  | 7,499 |  |  | 13,934 |
Other |  | 12 |  |  | — |  |  | 12 |  |  | 11 |  |  | — |  |  | 11 |
Total |  | $ | 12,743 |  |  | $ | 20,126 |  |  | $ | 32,869 |  |  | $ | 11,982 |  |  | $ | 18,994 |  |  | $ | 30,976 |
Schedule of Changes in Contract Liabilities | Changes in the contract liabilities during the period are as follows:
(in millions) |  |
Contract Liabilities: |  |
Balance at December 31, 2024 |  | $ | 568 |
Unearned revenue from cash received during the period |  | 382 |
Revenue recognized related to contract liability balance |  | (300) |
Balance at September 30, 2025 |  | $ | 650 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration